Please use this identifier to cite or link to this item:
Title: Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs
Authors: Grebely, Jason
Bruneau, Julie
Lazarus, Jeffrey V.
Dalgard, Olav
Bruggmann, Philip
Treloar, Carla
Hickman, Matthew
Hellard, Margaret
Roberts, Teri
Crooks, Levinia
Midgard, Havard
Larney, Sarah
Degenhardt, Louisa
Alho, Hannu
Byrne, Jude
Dillon, John F.
Feld, Jordan J.
Foster, Graham
Goldberg, David
Lloyd, Andrew R.
Reimer, Jens
Torrens, Marta
Wright, Nat
Maremmani, Icro
Norton, Brianna L.
Litwin, Alain H.
Dore, Gregory J.
Issue Date: 2017
Abstract: Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of HCV infection among current PWID also remains high in many settings. Morbidity and mortality due to liver disease among PWID with HCV infection continues to increase, despite the advent of well-tolerated, simple interferon-free direct-acting antiviral (DAA) HCV regimens with cure rates >95%. As a result of this important clinical breakthrough, there is potential to reverse the rising burden of advanced liver disease with increased treatment and strive for HCV elimination among PWID. Unfortunately, there are many gaps in knowledge that represent barriers to effective prevention and management of HCV among PWID. The Kirby Institute, UNSW Sydney and the International Network on Hepatitis in Substance Users (INHSU) established an expert round table panel to assess current research gaps and establish futureresearch priorities for the prevention and management of HCV among PWID. This round table consisted of a one-day workshop held on 6 September, 2016, in Oslo, Norway, prior to the International Symposium on Hepatitis in Substance Users (INHSU 2016). International experts in drug and alcohol, infectious diseases, and hepatology were brought together to discuss the available scientific evidence, gaps in research, and develop research priorities. Topics for discussion included the epidemiology of injecting drug use, HCV, and HIV among PWID, HCV prevention, HCV testing, linkage to HCV care and treatment, DAA treatment for HCV infection, and reinfection following successful treatment. This paper highlights the outcomes of the roundtable discussion focused on future research priorities for enhancing HCV prevention, testing, linkage to care and DAA treatment for PWID as we strive for global elimination of HCV infection. (C) 2017 Elsevier B.V. All rights reserved.
Notes: [Grebely, Jason; Dore, Gregory J.] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia. [Bruneau, Julie] Univ Montreal, Ctr Hosp, CHUM Res Ctr CRCHUM, Montreal, PQ, Canada. [Bruneau, Julie] Univ Montreal, Fac Med, Dept Family & Emergency Med, Montreal, PQ, Canada. [Bruneau, Julie] Univ Copenhagen, Rigshosp, CHIP, Copenhagen, Denmark. [Lazarus, Jeffrey V.; Dalgard, Olav] Hosp Clin Barcelona, Barcelona Inst Global Hlth ISGlobal, Barcelona, Spain. [Dalgard, Olav; Alho, Hannu] Akershus Univ Hosp, Dept Infect Dis, Lorenskog, Norway. [Bruggmann, Philip] Arud Ctr Addict Med, Zurich, Switzerland. [Treloar, Carla] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia. [Hickman, Matthew] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England. [Hellard, Margaret] Burnet Inst, Dis Eliminat Program, Melbourne, Vic, Australia. [Roberts, Teri] Med Sans Frontieres, Geneva, Switzerland. [Crooks, Levinia] Viral Hepatitis & Sexual Hlth Med, Australasian Soc HIV, Sydney, NSW, Australia. [Midgard, Havard] Univ Oslo, Inst Clin Med, Oslo, Norway. [Midgard, Havard] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway. [Larney, Sarah; Degenhardt, Louisa] UNSW Australia, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Alho, Hannu] Univ Helsinki, Helsinki, Finland. [Alho, Hannu] Natl Inst Hlth & Welf, Helsinki, Finland. [Byrne, Jude] Australian Injecting Illicit Drug Users League, Canberra, ACT, Australia. [Feld, Jordan J.] Ninewells Hosp & Med Sch, Dundee, Scotland. [Feld, Jordan J.] Univ Toronto, Sandra Rotman Ctr Global Hlth, Toronto Ctr Liver Dis, Toronto, ON, Canada. [Foster, Graham] Queen Mary Univ London, Liver Unit, London, England. [Goldberg, David] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland. [Goldberg, David] Hlth Protect Scotland, Glasgow, Lanark, Scotland. [Reimer, Jens] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany. [Robaeys, Geert] Dept Gastroenterol & Hepatol, Ziekenhuis Oost Limburg, Genk, Belgium. [Robaeys, Geert] UZ Leuven, Dept Hepatol, Leuven, Belgium. [Robaeys, Geert] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Torrens, Marta] Univ Autonoma Barcelona, IMIM Hosp Mar Med Res Inst, Inst Neuropsychiat & Addict, Hosp Mar, Barcelona, Spain. [Wright, Nat] Spectrum CIC, Wakefield, England. [Norton, Brianna L.; Litwin, Alain H.] Albert Einstein Coll Med, Dept Med, Div Gen Internal Med, Bronx, NY 10467 USA. [Norton, Brianna L.; Litwin, Alain H.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA. Univ Oslo, Oslo, Norway. [Alho, Hannu] Helsinki Univ Hosp, Abdominal Ctr, Helsinki, Finland. [Maremmani, Icro] Univ Pisa, Santa Chiara Univ Hosp, Pisa, Italy.
Keywords: HCV; Drug users; Injecting; IFN-free; PWID; DAA;HCV; Drug users; Injecting; IFN-free; PWID; DAA
Document URI:
ISSN: 0955-3959
e-ISSN: 1873-4758
DOI: 10.1016/j.drugpo.2017.05.019
ISI #: 000412613000007
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
grebely 1.pdf
  Restricted Access
Published version588.93 kBAdobe PDFView/Open    Request a copy
Show full item record


checked on Sep 5, 2020


checked on May 21, 2022

Page view(s)

checked on May 25, 2022


checked on May 25, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.